Hong Kong, 29 April 2019 

Essex Bio-Technology Limited (“EssexBio” or the “Group” or the Company, Stock code: 1061) today announced that the Company, Mitotech S.A. (“Mitotech”), a clinical-stage Luxembourg-based biotechnology company developing novel drug targeting mitochondria, together with Ora, Inc. (“Ora”), the world’s leading full-service ophthalmology CRO and product development firm, will jointly present the design of Phase 3 clinical trial, VISTA-1, exploring a First-in-Class ophthalmic mitochondrial reactive oxygen (mtROS) scavenger SkQ1 for the treatment of Dry Eye Disease (“DED”), at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting in Vancouver, Canada.
 
 
Details of poster are as follows:
 
Abstract Number: 6750 – B0274
Section Name: Cornea Dry Eye Clinical Treatment
Type: Poster
Date: Thursday, May 2, 2019, 10:15am – 12:00pm PT 
Location: West Exhibition Hall
Data Summary
 
SkQ1 ophthalmic solution is a first-in-class drug designed for protection of ocular surface from oxidative stress at mitochondrial level. In a previous Phase 2 study SkQ1 showed evidence of efficacy in reducing both the signs and symptoms in dry eye subjects.
 
About VISTA-1
 VISTA-1 is a multi-center, double-masked, randomized, placebo-controlled study comprising 5 visits over the course of approximately 9 weeks. Qualified subjects(n=444) are randomized 1:1:1 to receive either high dose SkQ1 ophthalmic solution(1.55ug/mL), low dose SkQ1 ophthalmic solution(0.155ug/mL), or placebo (vehicle of SkQ1 ophthalmic solution).
 
About ARVO
 The Association for Research in Vision and Ophthalmology, Inc. (ARVO) is the largest and most respected eye and vision research organization in the world. Its members include nearly 12,000 researchers from over 75 countries. ARVO advances research worldwide into understanding the visual system and preventing, treating and curing its disorders. The ARVO 2019 Annual Meeting will have the theme as “From bench to bedside and back”.
 
About Mitotech
 Mitotech S.A. is a clinical-stage Luxembourg-based biotechnology company developing novel drugs for the treatment of predominantly age-related disorders. The core technology behind Mitotech products is based on a novel class of small molecules – mitochondria targeting cardiolipin peroxidation inhibitors. Company’s lead compound SkQ1 is being developed in several drug formulations covering a variety of therapeutic areas with major focus on ophthalmology and neurodegenerative diseases. Mitotech successfully completed Phase II clinical study for Dry Eye Disease in the U.S. with other indications also approaching clinical stage of development.
 
About Ora
Ora is the world’s leading full-service ophthalmic CRO and product development firm with offices in the United States, the United Kingdom, Australia and Japan. Over the past 40 years, Ora has proudly helped its clients earn more than 47 product approvals. Ora supports a wide array of organisations, from start-ups to global pharmaceutical and device companies, to efficiently bring new products from concept to market. Ora’s pre- clinical and clinical models, unique methodologies and global regulatory strategies have been refined and
 
proven across thousands of global projects. Ora brings together the world’s most extensive and experienced team of ophthalmic experts and R&D professionals to maximise the value of product initiatives.